Royalty Pharma plc - Class A
Research Royalty Pharma plc - Class A (RPRX) on Bullrun: valuation model: 2.7% undervalued, market cap USD 25.76B, P/E 30.8, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRPRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal2.7% undervalued
- Market capUSD 25.76B
- P/E30.8
- Dividend yield1.6%
- Financial periodQ2 2026
- RevenueUSD 674.14M
- Net incomeUSD 17.88M
- Free cash flowUSD 728.46M
Valuation Snapshot
Bullrun's latest valuation model marks Royalty Pharma plc - Class A as 2.7% undervalued; latest market cap is USD 25.76B; P/E is 30.8; dividend yield is 1.6%.
Peer valuation comparison
Latest P/E is 30.76x versus a Healthcare sector median of 24.6x (25.0% above).
Latest dividend yield is 1.6% versus a Healthcare sector median of 1.84% (13.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.38B | USD 770.95M | USD 2.49B | n/a | 1.78 | USD 618.70M | USD 8.95B | USD 9.71B |
| FY2024 | USD 2.26B | USD 858.98M | USD 2.77B | n/a | 1.91 | USD 929.03M | USD 7.61B | USD 10.34B |
| FY2023 | USD 2.35B | USD 1.13B | USD 2.99B | n/a | 2.53 | USD 477.01M | USD 6.14B | USD 10.08B |
| FY2022 | USD 2.24B | USD 42.83M | USD 2.14B | n/a | 0.1 | USD 1.71B | USD 7.12B | USD 9.53B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 25.76B | 30.8 | 1.6% | 0.93 |
| 2025 | 2025-12-31 | USD 16.56B | 21.7 | 2.3% | 0.88 |
| 2024 | 2024-12-31 | USD 11.38B | 13.3 | 3.3% | 0.84 |
| 2023 | 2023-12-29 | USD 12.55B | 70.2 | 2.8% | 0.8 |
| 2022 | 2022-12-30 | USD 17.43B | 34.1 | 1.9% | 0.76 |
| 2021 | 2021-12-31 | USD 17.25B | 26.4 | 1.7% | 0.68 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.93 USD, yield 1.6%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.88 USD |
| FY2024 | 0.84 USD |
| FY2023 | 0.8 USD |
| FY2022 | 0.76 USD |
About Royalty Pharma plc - Class A
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
ETFs that hold Royalty Pharma plc - Class A
Royalty Pharma plc - Class A is one of the ten largest holdings of 3 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 1.85% | 0.35% |
| L&G Pharma Breakthrough UCITS ETF | 3.24% | 0.49% |
| VanEck Morningstar US SMID Moat UCITS ETF A Acc | 1.52% | 0.49% |
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Royalty Pharma plc - Class A overvalued or undervalued?
Bullrun's valuation model currently marks Royalty Pharma plc - Class A as 2.7% undervalued.
What is Royalty Pharma plc - Class A's market cap?
Royalty Pharma plc - Class A's market capitalization is USD 25.76B.
What is Royalty Pharma plc - Class A's P/E ratio?
Royalty Pharma plc - Class A's price-to-earnings (P/E) ratio is 30.8.
Does Royalty Pharma plc - Class A pay a dividend?
Royalty Pharma plc - Class A has a dividend yield of 1.6%.
What does Royalty Pharma plc - Class A do?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.